Meeting
2022 ASCO Genitourinary Cancers Symposium
Statin type and survival of patients with metastatic castrate-resistant prostate cancer receiving abiraterone and enzalutamide: A nationwide retrospective cohort study.
Authors
Harrison Yoon
University of Health Sciences and Pharmacy in St. Louis, St. Louis, MO
Harrison Yoon , Suhong Luo , Kristen Marie Sanfilippo , Travis Linneman , Alison Whitmer , Martin W. Schoen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 50)
DOI
10.1200/JCO.2022.40.6_suppl.050
Abstract #
50
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson
Poster
2019 Genitourinary Cancers Symposium
A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Munjid Al Harthy
Poster
2018 Genitourinary Cancers Symposium
Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan